Abstract:

Evaluation of neoadjuvant therapy for pancreatic carcinoma        YANG Yin-mo，MA Yong-su. Department of Surgery，Peking University First Hospital，Beijing 100034，China
Corresponding author：YANG Yin-mo，E-mail：yangyinmo@263.net
Abstract    Neoadjuvant therapy is recommended for patients with borderline resectable pancreatic carcinoma，although its usefulness in resectable disease still remains controversial. Neoadjuvant therapy should be offered as an alternative option to resectable pancreatic carcinoma who meet specific characteristics. There is a lack of consensus on cycles，regimens and criteria of resectability. Considering current results are based on retrospective studies and limited evidences，it is necessary to carry out a series of large，controlled randomized trials to objectively assess the benefits of neoadjuvant therapy for resectable pancreatic carcinoma.

Key words: pancreatic carcinoma, neoadjuvant therapy, resectable

摘要：

针对可能切除的胰腺癌行新辅助治疗后争取手术切除的治疗策略已渐成共识，对于可切除胰腺癌行新辅助治疗的意义仍存在争议，提倡对合并高危因素的可切除胰腺癌病人行新辅助治疗，但在“可切除”与“可能切除”的定义标准、化放疗方案选择、治疗周期等方面仍缺乏共识，目前结论多基于有限的小样本量的回顾性研究结果，循证等级不高，亟待开展大样本量的前瞻性对照研究，客观评价新辅助治疗在改善胰腺癌病人远期预后中的应用价值。

关键词: 胰腺癌, 新辅助治疗, 可切除